Hikal Limited · NSE:HIKAL
Hikal — Q1 FY26 Earnings Presentation
29 slides from Hikal's earnings presentation, August 2025
Slide 1: Investor Presentation Q1 FY26
Investor Presentation Q1 FY26 August, 2025
Slide 2: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Hikal Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and
Slide 3: Leading with Vision
Leading with “The global chemical and life sciences industry continues to face mitigated headwinds, marked by a gradual pickup in demand and capacity utilization, though pricing remains under pressure in some segments. Escalating tariff uncertainties and ongoing trade realignments have added a Visio
Slide 4: Q1FY26: Performance at a Glance
Q1FY26: Performance at a Glance
Slide 5: Q1FY26: Consolidated Performance Summary
Q1FY26: Consolidated Performance Summary CONSOLIDATED: FINANCIAL SUMMARY COMMENTARY Rs. In Crs Q4FY25 Q1FY25 Q1FY26 Revenue recorded at Rs 380 Crore; impacted by deferred Revenue 552 407 380 offtake post USFDA OAI in May 2025 EBITDA 124 58 25 Regulatory audits of Bangalore facilities by ANVISA, Braz
Slide 6: Q1FY26: Pharmaceuticals Performance Summary
Q1FY26: Pharmaceuticals Performance Summary PHARMACEUTICALS: FINANCIAL SUMMARY COMMENTARY Rs. In Crs Q4FY25 Q1FY25 Q1FY26 Revenue declined due to short-term pause in customer Revenue 351 229 203 offtake post-OAI status EBIT 55 9 (26) Regulatory audits of Bangalore facilities by ANVISA, Brazil and PM
Slide 7: Q1FY26: Crop Protection Performance Summary
Q1FY26: Crop Protection Performance Summary CROP PROTECTION: FINANCIAL SUMMARY COMMENTARY Rs. In Crs Q4FY25 Q1FY25 Q1FY26 Revenue for the quarter remains flat as anticipated Revenue 201 177 178 We witnessed volume growth however margins remain EBIT 36 21 17 under pressure The Crop Protection industr
Slide 8: Q1FY26: Consolidated P&L
Q1FY26: Consolidated P&L Particulars (Rs. In crores) Q1FY26 Q1FY25 YoY Q4FY25 QoQ Revenue 380 407 (6.5)% 552 (31.1)% Expenditure 356 349 429 EBITDA 25 58 (57.4)% 124 (80.0)% EBITDA Margin 6.5% 14.3% (778)bps 22.4% (1585)bps Other Income 1 1 1 Depreciation 39 32 38 Interest 17 20 18 PBT (31) 7 (539.1
Slide 9: Historical Performance Highlights
Historical Performance Highlights
Slide 10: Historical: Consolidated P&L Highlights
Historical: Consolidated P&L Highlights Rs. In crores REVENUE EBITDA PAT 2,023 161 341 328 1,943 323 133 257 267 1,860 91 1,785 78 70 1,720 FY21 FY22 FY23 FY24 FY25 FY21 FY22 FY23 FY24 FY25 FY21 FY22 FY23 FY24 FY25 10
Slide 11: Historical: Segmental Highlights
Historical: Segmental Highlights Rs. In crores REVENUE EBIT REVENUE SPLIT % 1,168 170 151 1,130 137 1,115 41% 44% 41% 35% 42% 1,100 93 PHARMA 65 1,060 59% 56% 59% 65% 58% FY21 FY22 FY23 FY24 FY25 FY21 FY22 FY23 FY24 FY25 FY21 FY22 FY23 FY24 FY25 REVENUE EBIT REVENUE SPLIT % 908 813 115 684 692 103 1
Slide 12: Consolidated Balance Sheet
Consolidated Balance Sheet Assets (Rs. In Crore) Mar-25 Mar-24 Equities & Liabilities (Rs. Crore) Mar-25 Mar-24 Total Non Current Assets 1,533 1,520 Shareholders Fund 1,263 1,188 Property, Plant and Equipment 1293 996 Share Capital 25 25 Capital work in Progress 121 414 Other Equity 1,238 1,163 Righ
Slide 13: Consolidated Cash Flow Statement
Consolidated Cash Flow Statement Particulars (Rs. In Crore) Full Year ended 31-Mar-25 Full Year ended 31-Mar-24 Profit before tax 124 95 Adjustments 215 175 Operating Profit Before Working Capital Changes 339 270 Change in operating assets and liabilities (29) (53) Cash generated from operations 310
Slide 14: Historical: Ratios
Historical: Ratios ROE% ROCE% 21.60% 16.10% 15.00% 15.30% 9.90% 8.50% 8.20% 7.10% 6.10% 7.30% FY21 FY22 FY23 FY24 FY25 FY21 FY22 FY23 FY24 FY25 NET DEBT / EQUITY (X) NET DEBT / EBITDA (X) 0.70 2.60 2.30 2.10 1.80 1.80 0.60 0.60 0.60 0.60 FY21 FY22 FY23 FY24 FY25 FY21 FY22 FY23 FY24 FY25 14
Slide 15: Corporate Snapshot
«Corporate Snapshot L
Slide 16: Our Vision & Mission
Our Vision & Mission VISION To be the leading global fine chemical company to the Pharmaceutical, Crop Protection, and Specialty Chemical Industries 01 02 MISSION To create value through superior, chemical products and operate as a responsible company. Building trust and respect of our customers, sh
Slide 17: Key Milestones
Key Milestones Years 1988 1991 1995 1997 2000 2001 2009 2014 2021 2024 Founded Listed on Acquired the New R&T Signed 10- by Jai Bombay Stock manufacturing Centre year multi Hiremath Exchange & site from established & product Key Event as a National Stock Novartis in Tokyo office to contract with che
Slide 18: Domestic & Global Presence
Domestic & Global Presence We Service Clients Globally Through our Global Footprint Panoli Europe Taloja Japan USA Pune Navi Mumbai India Bengaluru Mahad Corporate HQ R&T center, Integrated Mini Plant Manufacturing Site We serve markets across Americas, Europe, ME & We have offices across USA, Europ
Slide 19: Manufacturing Capabilities
Manufacturing Capabilities Pharmaceuticals Crop Protection Jigani Unit 1, Karnataka Mahad, Maharashtra • US FDA Approved API and Advanced Intermediates • First Manufacturing Facility of Hikal Manufacturing Site • Specialty Chemicals, Fungicides, Herbicides, and • cGMP Multipurpose API Facilities. In
Slide 20: Our state-of-the-art R&T facility
Our state-of-the-art R&T facility 15 4 Synthetic Instrumentation Laboratories Labs 1 1 Process Effluent Safety Treatability Lab Lab 1 1 Innovation Simulation 1 1 Lab Lab Kilo Lab Solid State (Scale up & Pilot) Chemistry Lab 1 6 Process High Development Pressure Lab Lab >250 26 Post PhD Graduates 20
Slide 21: Key Operational Metrics
Key Operational Metrics Pharmaceuticals Crop Protection 5 Manufacturing facilities 31 74 Commercialized Active DMFs Products 31 4,350MT $60Mn Commercialized Active Ingredients Capex invested in new Assets APIs Sold in FY25 440MT Advanced Intermediates 1 Kilo lab Sold in FY25 (Scale up & Pilot) 3000+
Slide 22: Our Commitment to Society
Our Commitment to Society 22
Slide 23: ESG Strategy
ESG Strategy E nvironment S ocial G overnance Decarbonization Health and safety Fair sourcing Employee Customers Community relations Governance & Material circularity corruption Diversity & inclusion Transparency & risk Water management management 23
Slide 24: ESG – Key Initiatives
ESG – Key Initiatives Our efforts have been recognized by leaders in sustainability assessment • Baselining for GHG1&2 • Material Topics Identification PHASE 1 • GHG Reduction Targets (SBTIs) Initiation Program (Completed) • Deployment of ESG Platform • Evaluation of ESG readiness and performance vs
Slide 25: Regulatory Approvals
Regulatory Approvals Key Regulatory Approvals Integrated Management Systems across all sites 25
Slide 26: Recognitions & Achievements
Recognitions & Achievements
Slide 27: Awards & Accolades
Awards & Accolades Employer of the Year Award TISS Leapvault CLO Awards 2024 The Great Managers Award 2024 Received at the India HR Summit & (November 2024) Ranked among the Top 50 Companies Awards (December 2024) for • Gold Award: Skill Development Initiative with Great Managers by People Business
Slide 28: Awards & Accolades
Awards & Accolades ET NOW Best Organizations for Women WOW Workplace Award 2025 The 5th Edition of ET NOW Best Organizations for Hikal has been recognized as one of the WOW Women celebrates organizations in India that excel in Workplaces of 2025 in the Manufacturing & Allied empowering women and adv
Slide 29: Thank You
Thank You Company: Investor Relations Advisors : Hikal Limited Strategic Growth Advisors Pvt. Ltd CIN: L24200MH1988PTC048028 CIN: U74140MH2010PTC204285 Mr. Kuldeep Jain Mr. Jigar Kavaiya / Ms. Ami Parekh Kuldeep_jain@hikal.com +91-9920602034 / +91-8082466052 jigar.kavaiya@sgapl.net/ ami.parekh@sgapl